纤溶酶原补充逆转脓毒症诱导的弥散性血管内凝血中的纤溶不足:一项先导研究
该先导研究纳入60例脓毒症诱导凝血病患者,随机接受12 mL/kg的OctaplasLG®或生理盐水安慰剂,检测功能性纤溶酶原、纤溶酶生成及纤溶标志物。患者基线纤溶酶原和纤溶酶生成显著低于健康对照;OctaplasLG®显著提高功能性纤溶酶原(+46 nM vs -84 nM)并改善纤溶酶生成(0.12 vs -0.36 fmol)。纤溶酶-抗纤溶酶复合物、纤溶酶原激活物抑制剂-1和组织型纤溶酶原激活物未见变化。接受OctaplasLG®者死亡率有降低趋势(42.3% vs 60.0%),但未达统计学显著。脓毒症DIC小鼠模型同样显示功能性纤溶酶原和纤溶酶生成降低,补充纤溶酶原后恢复。
要点
- 脓毒症诱导凝血病患者基线功能性纤溶酶原和纤溶酶生成显著低于健康对照。
- OctaplasLG® 12 mL/kg输注后功能性纤溶酶原变化为+46 nM([-96; 118]),安慰剂为-84 nM([-180; 27]),组间比较p<0.05。
- OctaplasLG®组纤溶酶生成变化为0.12 fmol([-0.25; 1.27]),安慰剂组为-0.36 fmol([-1.58; 0.12]),p<0.05。
- 纤溶酶-抗纤溶酶复合物、纤溶酶原激活物抑制剂-1、组织型纤溶酶原激活物水平未见变化。
- OctaplasLG®组死亡率42.3% vs 安慰剂组60.0%,为非显著降低趋势。
适用人群与场景
- 60例脓毒症诱导凝血病患者,随机接受OctaplasLG®或安慰剂。
- 脓毒症诱导DIC小鼠模型(转基因TMpro/pro小鼠)用于平行实验。
处置流程与药物剂量
- 患者随机接受12 mL/kg的OctaplasLG®(病原体灭活混合人血浆,含2 µM纤溶酶原)或12 mL/kg安慰剂(NaCl 0.9%)静脉输注。
- 小鼠模型接受纯化纤溶酶原或安慰剂。
研究设计与关键结果
- 先导研究:60例脓毒症诱导凝血病患者随机接受OctaplasLG®或安慰剂,检测输注前后功能性纤溶酶原、纤溶酶生成及纤溶标志物。
- 患者基线功能性纤溶酶原和纤溶酶生成显著低于健康对照。
- OctaplasLG®组功能性纤溶酶原变化+46 nM([-96; 118])vs 安慰剂组-84 nM([-180; 27]),p<0.05。
- OctaplasLG®组纤溶酶生成变化0.12 fmol([-0.25; 1.27])vs 安慰剂组-0.36 fmol([-1.58; 0.12]),p<0.05。
- 纤溶酶-抗纤溶酶复合物、纤溶酶原激活物抑制剂-1、组织型纤溶酶原激活物水平未见变化。
- OctaplasLG®组死亡率42.3% vs 安慰剂组60.0%,为非显著降低趋势。
- 脓毒症DIC小鼠功能性纤溶酶原100 nM([66-126])vs 对照295 nM([268-343]),纤溶酶生成1.8 fmol([1.4-2.1])vs 3.0 fmol([2.8-3.3]),p<0.05;补充纤溶酶原后功能性纤溶酶原346 nM([287; 360]),纤溶酶生成4.1 fmol([3.7; 5.5])。
证据类型、等级与局限
- 证据类型:先导研究(随机对照试验)及小鼠模型实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,补充纤溶酶原可恢复纤溶能力,支持其在脓毒症诱导DIC中的治疗潜力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Sepsis-induced disseminated intravascular coagulation (DIC) is characterized by impaired fibrinolysis, partly due to neutrophil elastase-mediated plasminogen degradation. We aimed to evaluate whether plasminogen supplementation could restore fibrinolytic capacity in patients with sepsis-induced coagulopathy and in a murine model of septic DIC.
METHODS: 60 patients with sepsis-induced coagulopathy were randomized to receive 12 mL/kg of placebo (NaCl 0.9%) or OctaplasLG®, a pathogen-inactivated pooled human plasma containing 2 µM plasminogen. Pre- and post-infusion levels of functional plasminogen, plasmin generation, and fibrinolysis markers (plasmin-antiplasmin complexes, plasminogen activator inhibitor-1, and tissue-type plasminogen activator) were measured. In parallel, in a sepsis-induced DIC model, transgenic TMpro/pro mice received either purified plasminogen or placebo. Functional plasminogen levels and plasmin generation were assessed via enzymatic assays.
RESULTS: In patients, baseline plasminogen and plasmin generation were significantly lower than in healthy controls. OctaplasLG® significantly increased functional plasminogen (+ 46 nM [-96; 118] vs. -84 [-180; 27] nM, p < 0.05) and improved plasmin generation (0.12 [-0.25; 1.27] vs. -0.36 [-1.58; 0.12] fmol, p < 0.05). No changes were observed in plasmin-antiplasmin, plasminogen activator inhibitor-1, or tissue-type plasminogen activator levels. A non-significant trend toward reduced mortality was noted in patients receiving OctaplasLG® (42.3% vs. 60.0%). Septic DIC-mice also exhibited reduced functional plasminogen (100 [66-126] vs. 295 [268-343] nM) and impaired plasmin generation (1.8 [1.4-2.1] vs. 3.0 [2.8-3.3] fmol, p < 0.05), which were restored after plasminogen supplementation (plasminogen: 346 [287; 360] nM; plasmin generation: 4.1 [3.7; 5.5] fmol).
CONCLUSION: Plasminogen supplementation restores fibrinolytic capacity, supporting its therapeutic potential in sepsis-induced DIC.
参考来源
- Tschirhart M, Curtiaud A, Abou Rjeily R, et al. Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study. Intensive Care Med. 2026. PMID: 41739188. doi:10.1007/s00134-026-08338-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。